@article{ref1,
title="Simulated driving changes in young adults with ADHD receiving mixed amphetamine salts extended release and atomoxetine",
journal="Journal of attention disorders",
year="2009",
author="Kay, G. G. and Michaels, M. Alex and Pakull, B.",
volume="12",
number="4",
pages="316-329",
abstract="BACKGROUND: Psychostimulant treatment may improve simulated driving performance in young adults with attention-deficit/hyperactivity disorder (ADHD). METHOD: This was a randomized, double-blind, placebo-controlled, crossover study of simulated driving performance with mixed amphetamine salts-extended release (MAS XR) 50 mg/day (Cohort 1) and atomoxetine 80 mg/day (Cohort 2) in young adults with ADHD. RESULTS: Adults aged 19 to 25 years with AD/HD (N = 19) who were administered MAS XR significantly improved overall simulated driving performance versus placebo up to 12 hours after dosing. In contrast, there were no statistically significant differences in simulated-driving-performance scores between atomoxetine and placebo. At endpoint, MAS XR reduced ADHD Rating Scale scores > or = 30% in 80% of subjects, whereas atomoxetine achieved this level of improvement for 40%. Limitations: Small sample size and use of simulated driving may limit generalizability of the findings. CONCLUSION: MAS XR in young adults with ADHD yields significant improvements in simulated driving performance and ADHD symptoms.<p /><p>Language: en</p>",
language="en",
issn="1087-0547",
doi="10.1177/1087054708322986",
url="http://dx.doi.org/10.1177/1087054708322986"
}